Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Market Cap | $111,643 | $97,897 | $170,094 | $145,467 |
| - Cash | $1,271 | $915 | $12,360 | $29,128 |
| + Debt | $232 | $175 | $221 | $259 |
| Enterprise Value | $110,604 | $97,157 | $157,955 | $116,598 |
| Revenue | $0 | $210 | $2,469,000 | $513 |
| % Growth | -100% | -100% | 481,656.1% | – |
| Gross Profit | -$37 | $49 | $2,468,958 | $127 |
| % Margin | – | 23.3% | 100% | 24.9% |
| EBITDA | -$12,661 | -$10,965 | -$13,729 | -$13,081 |
| % Margin | – | -5,221.4% | -0.6% | -2,552.4% |
| Net Income | -$12,554 | -$9,811 | -$13,491 | -$12,947 |
| % Margin | – | -4,671.9% | -0.5% | -2,526.2% |
| EPS Diluted | -0.39 | -0.32 | -0.44 | -0.45 |
| % Growth | -21.9% | 27.3% | 2.2% | – |
| Operating Cash Flow | -$7,335 | -$6,209 | -$6,492 | -$4,937 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7,335 | -$6,209 | -$6,492 | -$4,937 |